Voyager Therapeutics Inc. Company Profile
NASDAQ: VYGRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Voyager Therapeutics at a glance
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Lexington, MA. Voyager Therapeutics is led by Dr. Alfred W. Sandrock Jr., M.D., Ph.D. and employs about 141 people. The company's shares have traded publicly since 2015.
At a market capitalization of $151.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001640266, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Voyager Therapeutics do?
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Voyager Therapeutics Inc.
- Ticker
- NASDAQ: VYGR
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
- Employees
- 141
- Headquarters
- 75 Hayden Avenue, Lexington, MA, United States
- Phone
- 857 259 5340
- Website
- voyagertherapeutics.com
- IPO year
- 2015
- Market cap
- $151.58M
- SEC CIK
- 0001640266
Companies similar to Voyager Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABOSAcumen Pharmaceuticals Inc. | 2.10 | +3.45% | $151.87M | vs VYGR |
| TARAProtara Therapeutics Inc. | 2.59 | +1.37% | $153.06M | vs VYGR |
| CHRSCoherus Oncology Inc. | 1.01 | -1.94% | $156.05M | vs VYGR |
| MOLNMolecular Partners AG ADR | 3.81 | +0.79% | $145.94M | vs VYGR |
| OTLKOutlook Therapeutics Inc. | 0.59 | +3.15% | $143.63M | vs VYGR |
| CRDLCardiol Therapeutics Inc. Class A | 1.32 | +0.76% | $160.40M | vs VYGR |
| AVXLAnavex Life Sciences Corp. | 1.53 | -4.38% | $141.83M | vs VYGR |
| ARMPArmata Pharmaceuticals Inc. | 3.81 | -1.04% | $141.66M | vs VYGR |